Clinical Trials Insight: 700053496
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2011
At a glance
- Drugs IPI 940 (Primary)
- Indications Inflammatory pain; Neuropathic pain
- Focus Adverse reactions
- Sponsors Infinity Pharmaceuticals
- 07 Jan 2011 Infinity Pharmaceuticals expect commencement of the phase I development to be initiated, according to an Infinity Pharmaceuticals media release.
- 12 Feb 2010 New trial record.